Arvinas (ARVN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 24, 2026, with voting available online until June 23, 2026.
Shareholders are encouraged to review proxy materials online or request copies before voting.
Voting matters and shareholder proposals
Election of two Class II directors: Leslie V. Norwalk, Esq. and Randy Teel, Ph.D., both recommended by the board.
Advisory vote to approve compensation of named executive officers.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Proxies may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends both director nominees for election to Class II positions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Arvinas
- Vepdegestrant improved median PFS by 2.9 months over fulvestrant in ESR1-mutant breast cancer.ARVN
Study Update8 Jul 2026 - Phase III vepdegestrant data and new combination results are set to drive multiple launches and pipeline growth.ARVN
2024 Cantor Fitzgerald Global Healthcare Conference8 Jul 2026 - Q1 2025 saw revenue and net income surge, with restructuring extending cash runway into 2H 2028.ARVN
Q1 20258 Jul 2026 - All voting items passed at the virtual meeting, with no shareholder questions submitted.ARVN
AGM 202624 Jun 2026 - First PROTAC approval, focused pipeline, and key clinical milestones ahead in PSP and SBMA.ARVN
Jefferies Global Healthcare Conference 20264 Jun 2026 - FDA approved VEPPANU, the first PROTAC degrader, amid Q1 net loss and strong cash reserves.ARVN
Q1 202618 May 2026 - Shareholders will vote on directors, executive pay, and auditor ratification, with strong governance and ESG focus.ARVN
Proxy filing29 Apr 2026 - Improved financials and pipeline progress set stage for key 2026 milestones and FDA review.ARVN
Q4 20259 Apr 2026 - Phase I pipeline advances, vepdegestrant nears FDA decision, and key data readouts expected in 2024.ARVN
Barclays 28th Annual Global Healthcare Conference10 Mar 2026